Oligonucleotide Synthesis Market Overview

Oligonucleotides represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized pharmacological interventions.

The global oligonucleotide synthesis market size is estimated to be worth $ 4.8 billion in 2024 and is expected to grow at compounded annual growth rate (CAGR) of 9.9% during the forecast period 2024-2035.

Although oligonucleotides offer significant profit margins and have demonstrated the potential to treat a myriad of disease indications, they are generally associated with high costs of development and complex manufacturing protocols. This has compelled many oligonucleotide therapeutics developers to outsource various aspect of their operations to oligonucleotide synthesis providers.

Oligonucleotide Synthesis Market Segmentation

Oligonucleotide Synthesis Market focuses on Application Area (Research and Diagnostics, and Therapeutics), Type of Product Synthesized (Active Pharmaceutical Ingredients and Finished Dosage Forms), Type of Oligonucleotide Synthesized (Antisense, DNA, siRNA and Other Oligonucleotides), Scale of Operation (Clinical and Commercial), Therapeutic Area (Cardiovascular Disorders, Genetic Disorders, Liver Disorders, Rare Diseases, and Other Disorders), End-Users (Pharmaceutical / Biopharmaceutical Companies, Academic and Research Institutes, and Hospitals), Company Size (Small, Mid-sized, and Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World).

The oligonucleotide synthesis market is presently characterized by the presence of both niche, specialty oligonucleotide synthesis companies, focused on early-stage development and production (preclinical and / or clinical scales), and one-stop-shops, which have, over time, acquired an extensive range of capabilities to cater to essentially all the product development and commercialization requirements of sponsors.

It is worth highlighting that there is a significant rise in the interest of stakeholders in oligonucleotide synthesis segment; this can be validated by the increase in partnership and funding activity within this domain.

Oligonucleotide Synthesis Market Key Players

Examples of key oligonucleotide synthesis companies include Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Merck, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, Thermo Fisher Scientific, TriLink Biotechnologies.  

Further, the growing demand for oligonucleotides has compelled the players engaged in this domain to expand their existing capabilities / capacities in order to accommodate the future needs of their clients. In addition, as mentioned earlier, innovation in this field, coupled to the development of novel fermentation technologies, has further expeditated the growth of oligonucleotide synthesis segment.

The contract manufacturing market for oligonucleotides is highly fragmented, featuring the presence of established companies, as well as emerging start-ups. Close to 45% of the companies engaged in this domain are headquartered in North America; of these, 14% are mid-sized players followed by 13% each of large and small firms. About 72 companies synthesize RNA oligonucleotides, such as 49 companies are into small interfering RNA (siRNA), 25 into micro-RNA (miRNA) and 8 in Decoy RNA.

This can be attributed to the various advantages offered by RNA oligonucleotides, including high specificity, gene expression regulation and relative safety. In addition, close to 45% of the synthesis providers offer services across all scales of operations. Further, close to 90% of the players offer purification services. Presently, over 110 synthesis providers claim to have the necessary capabilities to offer oligonucleotide synthesis services; majority of these firms are based in North America.

Browse Complete Report at: https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organizations worldwide.

All our analysts are trained to produce high-quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.

Contact Details

Roots Analysis 

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com 

Website: https://www.rootsanalysis.com/